You are here
The 230-acre site in Sanford, North Carolina, just south of the famed Research Triangle, is home to one of the largest U.S. biotechnology hubs. The site has flexible, multi-product manufacturing capabilities and facilities focused on vaccines intermediates and drug substance, and gene therapy drug substance and drug product.
The vaccine manufacturing capabilities center on large-scale microbial fermentation, purification, conjugation and cell banking. Gene therapy capabilities include cell culture, purification, drug product formulation and filling, and inspect, label and primary packaging.
Sanford has been certified as a Carolina STAR site since 2007; the equivalent of an OHSA VPP certification recognizing safety excellence.
In 2017, Pfizer invested $100 million in a state-of-the-art gene therapy facility where clinical trial material drug substances and drug products are produced for Duchenne Muscular Dystrophy, hemophilia B and hemophilia A gene therapy candidates. In 2019, Pfizer announced an additional investment of $500 million for the construction of its facility for the production of gene therapies.